Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Diabets

- PMLiVE

Regeneron announces results for preventing lean mass and muscle loss during GLP-1 weight loss

Results show trevogrumab prevents lean mass and muscle loss during GLP-1 weight loss

- PMLiVE

Novo Nordisk to lower list price, or wholesale acquisition cost, for Wegovy and Ozempic

The reduction in price to $675 will take effect at the beginning of next year

- PMLiVE

Eli Lilly’s oral weight-loss candidate orforglipron shows promise in late-stage trial

The company is planning to submit the candidate for regulatory review by the end of the year

- PMLiVE

Novo Nordisk’s Ozempic granted FDA approval in chronic kidney disease

The progressive condition affects approximately 40% of type 2 diabetes patients

- PMLiVE

Merck gains rights to Hansoh’s preclinical GLP-1 candidate in deal worth $2bn

The company will evaluate the asset’s potential to provide cardiometabolic benefits beyond weight reduction

- PMLiVE

Pfizer to advance once-daily formulation of oral GLP-1 receptor agonist danuglipron

The drugmaker said last year that it would be dropping its twice-daily formulation of the candidate

- PMLiVE

Novo Nordisk shares positive phase 3 results for Ozempic in diabetes and chronic kidney disease

Approximately 40% of people living with type 2 diabetes will develop CKD

- PMLiVE

Novo Nordisk shares promising phase 3 data for semaglutide in diabetes and chronic kidney disease

An estimated 40% of people living with type 1 or type 2 diabetes will develop CKD in their lifetime

- PMLiVE

Novo Nordisk announces $2.3bn investment to expand production site in France

The investment will increase the manufacturing capacity for Novo's GLP-1 products

- PMLiVE

Eli Lilly announces $450m investment in US manufacturing site

In December 2022 increased demand resulted in a short supply of two of its diabetes drugs

- PMLiVE

Novo Nordisk reveals positive results at ADA 2021 for higher-dose Ozempic in type 2 diabetes

Ozempic 2 mg demonstrated a 2.2% reduction in blood sugar compared with a 1.9% reduction for those receiving Ozempic 1 mg

- PMLiVE

Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures

Earnings were particularly impacted by lower demand for top diabetes drug Trulicity

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links